Diagnósticos da América : 3Q25 saw 12% Diagnostics revenue growth, 26.5% EBITDA margin, and leverage down to 2.38x

About this update from Diagnosticos Da America S.a.

Gross revenue grew to R$2.9 billion in 3Q25, with Diagnostics up 12% and Hospitals and Oncology NE up 7% year-over-year. EBITDA margin improved to 26.5%, and leverage dropped to 2.38x, reflecting strong operational efficiency and capital structure improvements.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Diagnosticos Da America S.a.